Glaukos (NYSE: GKOS) — Perfil da empresa, notícias e dados financeiros
Glaukos develops advanced ophthalmic technologies aimed at improving treatment outcomes for eye diseases.
Glaukos
Glaukos (NYSE:GKOS) is an ophthalmic medical technology and pharmaceutical company committed to developing and commercializing breakthrough products and procedures designed to transform the treatment of eye diseases. The company's portfolio primarily focuses on advanced solutions for the treatment of glaucoma, corneal disorders, and retinal diseases. Glaukos is dedicated to leveraging its robust R&D capabilities to enhance and expand its product offerings, with the objective of improving clinical outcomes for patients suffering from eye diseases. Its innovative projects and products aim to provide long-term, sustainable value to patients, healthcare providers, and stakeholders alike.
Resumo
Operações
Produtos e/ou serviços de Glaukos
- iStent inject system for minimally invasive glaucoma surgery to improve aqueous humor outflow.
- iDose TR sustained-release implant for delivering trabecular micro-bypass technology for glaucoma treatment.
- iStent infinite for severe open-angle glaucoma treatment, designed for use in a standalone procedure.
- Avedro's corneal cross-linking technology to strengthen corneal tissue for keratoconus patients.
- iStent SA, a standalone ab interno gel stent designed for patients with open-angle glaucoma.
- Pharos excimer laser for precise, high-control dermatological treatments.
equipe executiva do Glaukos
- Thomas William BurnsChairman & CEO
- Joseph E. GilliamPresident & COO
- Alex R. ThurmanSenior VP & CFO
- Tomas NavratilChief Development Officer
- Christopher William LewisVice President of Investor Relations & Corporate Affairs
- Robert L. DavisSenior VP, General Counsel & Business Development
- Diana A. SchererVP of Compliance & Deputy General Counsel
- Michele M. AllegrettoSenior Vice President of Human Resources
- L. Jay KatzChief Medical Officer
- Tracy M. FoundsSenior Vice President of Global Quality & Medical Safety
Últimas notícias sobre a Glaukos
Principais indicadores financeiros
Resultados divulgados pela Glaukos , em USD.
- Cap. de mercado
- 10,7 bi
- Receita (TTM)
- 612,8 mi
- P/L
- —
- LPA (diluído, TTM)
- -3.3
- Dividend yield
- —
- Margem de lucro
- -30.7%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 507,4 mi | -86,7 mi | -187,7 mi | |
| 383,5 mi | -122,4 mi | -146,4 mi | |
| 314,7 mi | -128,7 mi | -134,7 mi | |
| 282,9 mi | -82,3 mi | -99,2 mi |